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Cetuximab and panitumumab bind the human epidermal growth factor receptor (EGFR). Although the chimeric cetuximab (IgG1)
triggers antibody-dependent-cellular-cytotoxicity (ADCC) of EGFR positive target cells, panitumumab (a human IgG2) does not.
The inability of panitumumab to trigger ADCC reflects the poor binding affinity of human IgG2 Fc for the FcγRIII (CD16) on
natural killer (NK) cells. However, both human IgG1 and IgG2 bind the FcγRII (CD32A) to a similar extent. Our study compares
the ability of T cells, engineered with a novel low-affinity CD32A131R-chimeric receptor (CR), and those engineered with the low-
affinity CD16158F-CR T cells, in eliminating EGFR positive epithelial cancer cells (ECCs) in combination with cetuximab or
panitumumab. After T-cell transduction, the percentage of CD32A131R-CR T cells was 74  10%, whereas the percentage of
CD16158F-CR T cells was 46  15%. Only CD32A131R-CR T cells bound panitumumab. CD32A131R-CR T cells combined with the
mAb 8.26 (anti-CD32) and CD16158F-CR T cells combined with the mAb 3g8 (anti-CD16) eliminated colorectal carcinoma (CRC),
HCT116FcγR+ cells, in a reverse ADCC assay in vitro. Crosslinking of CD32A131R-CR on T cells by cetuximab or panitumumab and
CD16158F-CR T cells by cetuximab induced elimination of triple negative breast cancer (TNBC) MDA-MB-468 cells, and the
secretion of interferon gamma and tumor necrosis factor alpha. Neither cetuximab nor panitumumab induced Fcγ-CR T
antitumor activity against Kirsten rat sarcoma (KRAS)-mutated HCT116, nonsmall-cell-lung-cancer, A549 and TNBC, MDA-MB-
231 cells. The ADCC of Fcγ-CR T cells was associated with the overexpression of EGFR on ECCs. In conclusion, CD32A131R-CR T
cells are efficiently redirected by cetuximab or panitumumab against breast cancer cells overexpressing EGFR.
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What’s new?
The role of antibody-dependent cellular cytotoxicity in the antitumor activity of tumor antigen-specific monoclonal antibodies
has stimulated interest in genetically engineering T cells with the CD16 chimeric receptor (CD16-CR). Here, the authors expand
the application of this methodology to triple negative breast cancer (TNBC) overexpressing EGFR by utilizing a novel
CD32A131R-CR in combination with anti-EGFR mAbs. The study supports the use of CD32A131R-CR T cells combined with either
panitumumab or cetuximab—an IgG2 and IgG1 monoclonal antibody, respectively—for targeting TNBC cells overexpressing
EGFR. The results may be utilized as a platform for designing therapies targeting TNBC overexpressing EGFR.
interest in genetically engineering T cells with the CD16 chi-
meric receptor (CD16-CR).7,8 In these cells, the extracellular
domain of CD16 was ligated to cytotoxic signaling molecules
fused with9,10 or without11,12 T-cell costimulatory molecules.
This strategy allows the rapid generation of polyclonal T cells
with a potent cytotoxic activity when combined with
mAbs, recognizing the TAs expressed on the tumor cell mem-
brane. Based on this background information, we utilized
cetuximab and panitumumab as a model to demonstrate that
CD32A131R-CR T cells have higher cytotoxic activity than
CD16158F-CR T cells because they eliminate ECCs in combi-
nation with both cetuximab and panitumumab. In the present
study, we engineered T cells with a novel second generation of
CD32A131R-CR. The antitumor activity of the CD32A131R-CR
T cells was compared to that of the CD16158F-CR T cells in
combination with cetuximab (IgG1) or panitumumab (IgG2).
Both engineered T cells, in combination with cetuximab,
exerted a significant antitumor activity against breast cancer
(BC) cells overexpressing the EGFR (EGFRhigh). However,
only the CD32A131R-CR T cells effected cytotoxicity against
EGFRhigh BC cells in combination with either cetuximab or
panitumumab. Our results strongly suggest that CD32A131R-
CR has the potential to be utilized in Fcγ-CR T-cell-based
immunotherapy of EGFR overexpressing BC cells.
Materials and Methods
Antibodies and reagents
Allophycocyanin (APC)-conjugated antihuman CD3 (cat.
555335), fluorescein isothiocyanate (FITC)-conjugated antihu-
man CD3 (cat. 555332), PerCP-Cy5.5-conjugated antihuman
CD4 (cat. 332772), APC-conjugated antihuman CD8 (cat.
555369), FITC-conjugated antihuman CD107A (cat. 555800),
FITC-conjugated antihuman CD279 (PD-1) clone MIH4 (cat.
557860), phycoerythrin (PE)-conjugated antihuman CD16
(cat. 555407), PE-conjugated antihuman CD32 (cat. 550586),
FITC-conjugated Annexin V (cat. 556420), propidium iodide
(PI) staining solution (cat. 5166211E), FITC-conjugated
mouse antihuman IgG (cat. 555786), FITC-conjugated goat
antimouse IgG (cat. 555988), mouse antihuman CD3 (cat.
555329) and antihuman CD28 (cat. 555725) were purchased
from BD Bioscience (San Jose, CA). PE-conjugated goat
antimouse IgG (1012-09) was purchased by Southern Biotech
(Birmingham, AL). Mouse antihuman CD16 (clone 3g8),
Introduction
The lytic activity of antibody-dependent-cellular-cytotoxicity 
(ADCC) is influenced by multiple variables, including the type 
of affinity by which the Fc fragment of an antibody binds to the
FcγR on a competent cytotoxic cell, the expression level of the 
targeted antigen on the surface of targeted cells and the associa-
tion constant of the antibody for the surface antigen of interest.1 
The FcγR family includes CD16, CD32 and FcγRI (CD64). In 
humans, CD16 and CD32 families are both composed of distinct 
variants. CD16 includes CD16A and CD16B. CD16A is 
expressed on NK cells and transduces activating signals through 
adaptor molecules containing immunoreceptor tyrosine-based 
activation motif (ITAM). CD16B is a glycosylphosphatidyl-inosi-
tol-anchored protein expressed on granulocytes, and it is likely 
to be involved in capturing immune complexes in the peripheral 
blood.2 CD32 is composed of three variants A, B and C. CD32A 
and C are activating molecules containing ITAM in the intracel-
lular tail. They are expressed on monocyte/macrophages and 
dendritic cells. In contrast, CD32B is an inhibitory molecule con-
taining immunoreceptor tyrosine-based inhibitory motif in 
the intracellular portion. It is expressed on all leukocytes with 
the exception of NK and T cells. CD32A and CD16A can be 
expressed in polymorphic forms, each of which displays a differ-
ent binding affinity for the Fc portion of IgG. The presence of 
valine at position 158 of CD16 (CD16158V) and of histidine at  
position 131 of CD32A (CD32A131H) identifies the high-affinity 
receptors, whereas the presence of phenylalanine at position 
158 (CD16158F) and of arginine at position 131 (CD32A131R) of  
CD16 and CD32A, respectively, defines the low-affinity recep-
tors.3 Moreover, the activity of ADCC is influenced by the mono-
clonal antibody (mAb) subclasses because distinct subclasses have 
different association constants for the FcγRs, CD16 and CD32A. 
Cetuximab (IgG1) and panitumumab (IgG2) are currently utilized 
to treat epidermal growth factor receptor (EGFR)-positive tumors. 
These two mAbs have demonstrated the differential ability to medi-
ate cell-dependent cytotoxicity against EGFR-positive epithelial can-
cer cells (ECCs).4 Only cetuximab mediates the CD16-positive 
natural killer (NK) cell-dependent cytotoxicity of ECCs. The differ-
ential activity of cetuximab and panitumumab reflects the low affin-
ity of IgG2 for the FcγR CD16.5 In contrast, CD32A binds both 
IgG1 and IgG2, although with a different affinity.3
The role of ADCC in the in vitro and in vivo antitumor activity of 
tumor antigen (TA)-specific mAbs6 has stimulated
mouse antihuman CD247 (CD3ζ) mAb (clone 6B10.2) and
mouse antihuman EGFR antibody (clone AY13) were pur-
chased from BioLegend (San Diego, CA). Antihuman CD32
mAb (clone 8.26) was purchased from BD Bioscience (San
Diego, CA). Antihuman B7-H3 (CD276) mAb 376.96 was
developed and characterized as previously described.13 mAb
376.96 was purified from ascitic fluid by affinity chromatogra-
phy on Protein A. The activity and purity of the mAb prepa-
rations was monitored using binding assays and SDS-PAGE.
Cetuximab (Erbitux) and panitumumab (Vectibix) were
obtained from Merck Serono (Darmstadt, Germany) and
Amgen (Thousand Oaks, CA), respectively. Antiphospho
Tyr142 (Y142) CD3ζ mAb (cat. ab68235) was purchased from
Abcam (Cambridge, U.K.). 3-(4,5-Dimethylthiazol-2-Yl)-
2,5-diphenyltetrazolium bromide (MTT) was obtained from
Sigma–Aldrich (Saint Louis, MO). FcR blocking reagent
(BR) was purchased from Miltenyi (Bergisch Gladbach, Ger-
many). GeneJuice® Transfection Reagent (Novagen) was
obtained from Millipore (Burlington, MA). Human recombi-
nant interleukin-7 (IL-7) and interleukin-15 (IL-15) were
obtained from PeproTech (London, U.K.). Lipofectamine
2000 was purchased from Life Technologies (Carlsbad, CA)
and Retronectin (Recombinant Human Fibronectin) was pur-
chased from Takara Bio (Saint-Germain-en-Laye, France).
Cell lines
The 293T (RRID:CVCL_0063) packaging cell line was used to
generate the helper-free retroviruses for T-cell transduction.
293T cells were cultured in Iscove’s Modified Dulbecco’s
Medium (IMDM) supplemented with 10% fetal bovine serum,
2 mM L-glutamine, 0.1 mg/ml streptomycin and 100 U/ml
penicillin, hereafter referred to as IMDM complete medium
(CM). The Kirsten rat sarcoma (KRAS)-mutated A549 (RRID:
CVCL_0023), HCT116 (RRID:CVCL_0291) and HCT116 cells
stably transfected with CD32A131R (HCT116CD32A131R), here-
after referred to as HCT116FcγR+ cells, were maintained in
Roswell Park Memorial Institute (RPMI)-1640 CM. KRAS-
mutated triple negative breast cancer (TNBC) cells, MDA-
MB-231 (RRID:CVCL_0062) and KRAS wild-type TNBC
cells, MDA-MB-468 (RRID:CVCL_0419), were cultured in
Dulbecco’s Modified Eagle’s Medium (DMEM) CM (Thermo
Fisher Scientific, Waltham, MA). The 293T cells were pro-
vided by Dr. Gianpietro Dotti, University of North Carolina,
Chapel Hill, NC. The A549 cells were provided by
Dr. Antonio Rossi, National Research Council, Italy. The
MDA-MB-231 and MDA-MB-468 cells were provided by
Dr. Maria Lucibello, National Research Council, Italy. The
HCT116 cells were provided by Dr. Giulio Cesare Spagnoli,
University of Basel, Switzerland. The mycoplasma-free cancer
cell lines utilized in our study are part of our lab collection.
An authentication test was successfully performed on
November 21, 2018 using PCR-single-locus-technology
(Eurofins, Ebersberg, Germany). The cell lines were passaged
for four to eight times before use, or kept in culture for a
maximum of 6 weeks.
CD32A131R-CR construction
The signal peptide (nucleotides 1-99) and the extracellular
region (nucleotides 100-648) of the low-affinity variant
CD32A131R were amplified by reverse-transcriptase polymer-
ase chain reaction (RT-PCR) from RNA extracted from
freshly isolated peripheral blood mononuclear cells (PBMCs)
using the following primers: forward 50-GAGAATTCACCAT
GACTATGGAGACCCAAATG-30 and reverse 50-CGTACG
CCCCATTGGTGAAGAGCTGCC-30 (Thermo Fisher Scien-
tific, Waltham, MA). The PCR product was fused in tandem
by restriction of the enzyme-compatible ends with the CD8α
transmembrane domain and the CD28 and CD3ζ intracellular
regions already available in the lab (CD32A131R-CR). The gen-
eration of CD16158F-CR has been previously described.10 The
CD32A131R-CR and CD16158F-CR genes were subcloned into
the NcoI and MluI sites of the SFG retroviral vector.
Retrovirus production and T-cell transduction
Retroviral supernatants were obtained by transient transfec-
tion of the 293T packaging cells, using the GeneJuice reagent,
with the following vectors: the Peg-Pam vector, containing the
Moloney murine leukemia virus gag and pol genes, the RDF
vector, containing the RD114 envelope and the CD32A131R-
CR or CD16158F-CR SFG retroviral vectors. Then, 48 hr and
72 hr posttransfection, the conditioned medium containing
the retrovirus was harvested, filtered, snap frozen and stored
at −80C until use. To generate the Fcγ-CR T cells, PBMCs
(0.5 × 106 PBMCs/ml) were cultured for 3 days in a nontissue
culture treated in a 24-well plate precoated with 1 μg/ml of
anti-CD3 and 1 μg/ml of anti-CD28 mAbs in the presence of
10 ng/ml of IL-7 and 5 ng/ml of IL-15. The viral supernatant
was loaded on RetroNectin-coated nontissue culture treated
24 well plates, and spun for 1.5 hr at 2,000g. The activated T
cells were seeded into the retrovirus loaded-plate, spun for
10min, and incubated for 72 hr at 37C in 5% CO2. After
transduction, the T cells were expanded in RPMI-1640 CM
supplemented with 10 ng/ml of IL-7 and 5 ng/ml of IL-15 for
12–13 days, and then analyzed.
Western blot
The CD32A131R-CR transduced and nontransduced T cells
were lysed with Triton buffer composed of 1% (v/v) Triton X-
100, 20 mM Tris–HCL pH 7.6, 137 mM NaCl, 1 mM MgCl2,
1 mM CaCl2, 2 mM phenylmethylsulfonyl fluoride sup-
plemented with phosphatase (Sigma–Aldrich, Saint Louis,
MO), and protease (Roche, Basel, Switzerland) inhibitor cock-
tails. Thirty micrograms of protein lysates were resolved on
Bolt 4–12% Bis–Tris plus gel (Invitrogen, Carlsbad, CA) under
reducing conditions, and then transferred to a nitrocellulose
filter. The filter was probed overnight at 4C with a mouse
antihuman CD3ζ or rabbit antiphospho-tyrosine CD3ζ
In the cytotoxic assay, MDA-MB-468 cells were seeded in
24-well plates at a concentration of 0.2 × 106cells/well. The
following day, CD16158F-CR T cells or CD32A131R-CR T cells
were added to the culture at E:T ratio of 1:1 for 4 hr at 37C
in the presence or absence of cetuximab, panitumumab or
376.96 mAb. The cells were then stained with PE-conjugated
antihuman EGFR mAb, FITC-Annexin V and PI solution and
analyzed by flow cytometry as previously described.14
Statistical analysis
The results were analyzed by using either the unpaired t-test
or the Mann–Whitney test. The relationship between the two
variables was measured using Spearman’s rank correlation
coefficient. Differences with a p-value <0.05 were considered
to be statistically significant.
Data availability
The data that support the findings of our study are available
from the corresponding author upon reasonable request.
Results
CD32A131R and CD16158F-CRs are differentially expressed
on T cells
The activated T cells were transduced in vitro with a gamma-
retroviral vector encoding the CD32A131R-CR (Fig. 1a). Then,
Western blot and flow cytometry analysis were used to test the
cells for expression of CD32A131R-CR. For biochemical analysis,
we used two mAbs specific for the nonphosphorylated and
phosphorylated CD3ζ chain. Both mAbs detected two distinct
bands. The molecular weight band slightly higher than 51 kDa
matches the expected size of the CD32A131R-CR while the
smaller 18 kDa band, detected in both the control and
CD32A131R-CR-expressing T cells, corresponds to the endoge-
nous CD3ζ chain (Fig. 1b). The flow cytometry results showed
that CD32A131R-CR was clearly detectable on the cell surface of
the engineered T cells (Fig. 1c, left panel). After a 3-day T-cell
transduction, both CD32A131R-CR and CD16158F-CR T were
found to be expressed on the surface of CD4 and CD8 T cells
(Fig. 1c, middle panel). Interestingly, CD32A131R-CR T cells
and to a lesser extent CD16158F-CR T cells expressed the check-
point inhibitor molecule PD-1 (Fig. 1c, right panel).
CD32A131R-CR specifically bound the Fc fragment of soluble
immunoglobulins
In the initial experiments, we compared the ability of the
CD32A131R-CR and CD16158F-CR T cells to bind to the soluble
IgG Fc fragment. As a model reagent, we chose the H4A3 mAb,
a FITC-conjugated IgG1 specific for CD107A, an intracellular
lysosomal-associated membrane protein (LAMP-1). First, we
evaluated the binding of anti-CD107A mAb on the surface of
the CD32A131R-CR T cells in comparison to the CD16158F-CR
T cells. After a 30 min incubation, the CD32A131R-CR T cells
effectively bound to the anti-CD107A mAb on their surfaces
(Fig. 2a, left panel), whereas CD16158F-CR did not (Fig. 2a, right
(Y142) antibody. The former was detected using a horseradish 
peroxidase-conjugated donkey antimouse (Jackson Laboratory, 
Bar Harbor, ME) for 1 hr at room temperature. Antibody 
binding was visualized with an Amersham ECL Western blot-
ting detection reagent (GE Healthcare, Little Chalfont, U.K.).
Binding assay
Direct immunofluorescence analysis was used to test the Fc 
antibody-binding ability of the FITC-conjugated anti-CD107A 
mAb to CD32A131R-CR and CD16158F-CR. The CD32A131R-CR 
and CD16158F-CR T cells were incubated with 5 μl of FITC-
conjugated anti-CD107A, with or without the FcR BR, for 
30 min at 4C. Then, the cells were washed and analyzed using 
flow cytometry. Cetuximab or panitumumab Fc fragment bind-
ing to the CD32A131R-CR or CD16158F-CR T cells was evalu-
ated by staining with an FITC-conjugated antihuman IgG.
Flow cytometry
Phenotypic analysis of transduced and nontransduced T cells 
was assessed by flow cytometry incubating the cells for 30 min 
at 4C with various combinations of the following mAbs 
including FITC-conjugated antihuman CD3, PE-conjugated 
antihuman CD32, PE-conjugated antihuman CD16, APC-
conjugated antihuman-CD8, PerCP-Cy5.5 antihuman CD4 
and FITC-conjugated antihuman PD-1. The cells were then 
analyzed using a 2-laser BD FACSCalibur flow cytometer 
(Becton Dickinson, Franklin Lakes, NJ). The results were ana-
lyzed using Tree Star, Inc. FlowJo software.
Cytokine release assay
The CD32A131R-CR or CD16158F-CR transduced T cells (2 × 
105/well) were added to 96-well plates, previously coated with 
10 μg/ml of anti-CD3, 3g8, or 8.26 mAbs. In the coculture 
experiments, the CD16158F-CR T cells or CD32A131R-CR 
T cells were plated in 96-well plates with target cell lines at a
5:1 E:T ratio in the presence or absence of 3 μg/ml of 
cetuximab or panitumumab or the anti-B7-H3 mAb, 376.96. 
Supernatants were collected 24 hr or 48 hr after culturing. 
The interferon gamma (IFNγ) and tumor necrosis factor 
alpha (TNFα) levels were measured using ELISA (Thermo 
Fisher Scientific, Waltham, MA).
In vitro tumor cell viability assay
The tumor target cells (7 × 103/well) were seeded into 96-well 
plates and CD16158F-CR T cells or CD32A131R-CR T cells 
(35 × 103/well) were added in the presence or absence 
cetuximab or panitumumab or the anti-B7-H3 mAb 376.96 
(3 μg/ml; see above). After 48 hr incubation at 37C, the non-
adherent T cells were removed. Then, a suspension of fresh
medium (100 μl/well) supplemented with MTT (20 μl/5 mg/ml) 
was added to the adherent cells for 3 hr at 37C. MTT was then
removed, and 100 μl of dimethyl sulfoxide was added to each 
well. Absorbance (optical density) was measured at 570 nm.
panel). Binding was highly specific, because it was abrogated in
the presence of FcR BR. To further evaluate whether the
CD32A131R-CR T cells were capable of binding to the mAb Fc
fragment in a more physiological condition, we tested whether
the Fc fragment-binding capacity of CD32A131R-CR was pre-
served in the presence of human immunoglobulins. Therefore,
we incubated anti-CD107A with the CD32A131R-CR T cells in a
buffer containing 10% of human plasma (Fig. 2b). After a
30 min incubation, anti-CD107A mAb was still bound to the
engineered T cells (Fig. 2b).
To assess the Fcγ-CR T-cell potential to target the EGFR+
ECCs upon incubation with the anti-EGFR mAbs, we tested
their antibody-binding capacity by using cetuximab and pan-
itumumab mAbs. Only the CD32A131R-CR T cells bound the
Fc fragment of both of the soluble anti-EGFR mAbs (Fig. 2c);
the binding capacity was higher for cetuximab than pan-
itumumab (Fig. 2c, lower panels). It is important to note that
the binding of both mAbs was prevented in the presence of
FcR BR (Fig. 2c). Finally, we performed dose–response binding
assays in which cetuximab was incubated at increasing concen-
trations with the Fcγ-CR T cells for 30 min at 4C. As shown
in Figure 2d, only the CD32A131R-CR T cells (solid lines) bound
cetuximab. The maximum binding capacity of CD32A131R-CR,
expressed as both percentages and mean fluorescence intensity
Figure 1. Molecular structure and expression efficiency of CD32A131R-chimeric receptor (CR) in T cells. (a) Schematic representation of the
CD32A131R-CR gene cloned into the SFG retroviral vector. The CR transgene included the signal peptide and the extracellular domain of
CD32A131R fused in tandem with the transmembrane region of CD8α and the intracellular signal motifs of CD28 and CD3ζ. (b) Western blot
analysis of CD3ζ expression in CD32A131R-CR T cells. The soluble fractions of the cell lysates were separated, under reducing conditions,
by SDS-PAGE gel electrophoresis and transferred on nitrocellulose filter membranes. Nonphosphorylated and phosphorylated CD3ζ were
immunoblotted using anti-CD3ζ and anti-phospho-Y142-CD3ζ mAbs, respectively. Lower bands refer to endogenous CD3ζ in both the
transduced and nontransduced T cells. Upper bands show the chimeric CD3ζ with the expected molecular weight specifically detected in the
transduced T cells. (c) After Fcγ-CR T-cell transduction, the cells were cultured for 3 days at 37C in the presence of IL-7 and IL-15. The
distribution of CD4 and CD8 on T cells was evaluated by a four-color flow cytometry assay. CD3 cells were stained with fluorescein
isothiocyanate (FITC)-anti-CD3, phycoerythrin (PE)-anti-CD32 or PE-anti-CD16, PerCp-Cy5.5-anti-CD4 and allophycocyanin (APC)-anti-CD8
mAbs. The distribution of PD-1 was analyzed on the transduced T cells with a PE-anti-CD32 or PE-anti-CD16 and FITC-anti-PD-1 mAbs. The
cells were analyzed by flow cytometry utilizing a BD-FACSCalibur™.
CD16158F-CR T cells significantly reduced the number of via-
ble HCT116FcγR+ cells, which is consistent with efficient Fc-
mediated cytotoxic activity. Furthermore, crosslinking of
either Fcγ-receptor with specific mAbs induced the release of
comparable amounts of IFNγ and TNFα (Fig. 3b). These data
indicate that both the CD32A131R-CR T cells and the
CD16158F-CR T cells clearly mediate comparable levels of
reverse ADCC when given in combination with the mAbs,
8.26 and 3g8, respectively.
CD32A131R-CR T cells and CD16158F-CR T cells differ in their
ability to eliminate MDA-MB-468 cells in combination with
cetuximab and panitumumab
The ability of CD32A131R-CR to specifically bind the
cetuximab Fc fragment prompted us to investigate whether
this binding triggers ADCC against EGFR+ ECC lines. The
Figure 2. Analysis of the binding of mAb Fc fragments to the CD32A131R-chimeric receptor (CR) and CD16158F-CR engineered T cells. The ability
of CD32A131R-CR T cells or CD16158F-CR T cells to specifically bind the Fc fragment of a fluorescein isothiocyanate (FITC)-conjugated anti-
CD107A mAb was assessed. After T cell transduction, the blast cells were incubated for 30 min at 4C, with or without FcR BR, in the absence
(a) or presence (b) of 10% of human plasma. The T cells were then washed and stained with fluorescent mAbs, specific for the indicated
markers, and analyzed by flow cytometry. The binding of cetuximab or panitumumab Fc fragment on the CD32A131R-CR T cells (c, left) or the
CD16158F-CR T cells (c, right) was evaluated upon incubation with 3 μg/ml of either cetuximab or panitumumab for 30 min at 4C, with or
without FcR BR. The cells were then washed and stained with an FITC-conjugated mouse antihuman IgG antibody (AH). The binding of
cetuximab and panitumumab was analyzed by flow cytometry. The maximum binding capacity of CD32A131R- and CD16158F-CRs by cetuximab
Fc fragment was determined in dose–response experiments (d). The CD32A131R-CR T cells (solid line) or CD16158F-CR T cells (dashed line)
were incubated with increasing doses of cetuximab for 30 min, washed and then incubated with FITC-conjugated mouse antihuman IgG
antibodies. The numbers in the quadrants refer to the percentages of positive cells. Abbreviations: BR, blocking reagent, NT; not transduced.
(MFI) of the positive cells, was achieved at concentrations of 
cetuximab ranging between 1 and 10 μg/ml. These results dem-
onstrate that the CD32A131R-CR T cells have a superior binding 
ability for soluble mAbs in comparison to the CD16158F-CR T 
cells.
CD32A131R-CR and CD16158F-CR T cells eliminate KRAS-
mutated HCT116FcγR+ cells in redirected ADCC assays and
release IFNγ and TNFα upon specific antigen stimulation 
Next, we tested the ability of the Fcγ-CR-transduced T cells to 
elicit cytotoxic activity in a reverse ADCC assay (Fig. 3a). The 
CD32A131R-CR T cells and CD16158F-CR T cells were incu-
bated with HCT116 cells, stably transfected with CD32A, in 
the presence of anti-CD32 mAb and anti-CD16 mAb, respec-
tively. Tumor cell viability was analyzed after 48 hr using the 
MTT assay. Incubation with either CD32A131R-CR T cells or
CD32A131R-CR T cells and CD16158F-CR T cells were incu-
bated with four ECC lines at an E:T ratio of 5:1. Tumor cell
viability was assessed after 48 hr incubation at 37C by an
MTT assay. The CD32A131R-CR T cells significantly reduced
the viability of the MDA-MB-468 cells in the presence of
cetuximab or panitumumab, but the CD16158F-CR T cells
were only effective in the presence of cetuximab (Fig. 4a). In
contrast, anti-B7-H3, 376.96 mAb, which stained the MDA-
MB-468 cells, did not cause detectable change in ECC viabil-
ity. Neither cetuximab nor panitumumab had detrimental
effects on the MDA-MB-468 cells in the absence of the Fcγ-
CR T cells (Fig. 4a). However, the CD32A131R-CR T cells and
CD16158F-CR T cells, in combination with cetuximab or pan-
itumumab, failed to affect the viability of the EGFR+ MDA-
MB-231, A549 and HCT116 cells (Fig. 4a).
To further demonstrate the cytotoxic effect of engineered
T cells, both CD16158F-CR and CD32A131R-CR T cells were
incubated, in the presence or absence of anti-EGFR mAbs,
with or without MDA-MB-468 cells. After a 4 hr incubation
at 37C, in 5% CO2, the cytotoxic activity of engineered
T cells on MDA-MB-468 cells was assessed by a flow cyto-
metry assay. Only CD16158F-CR T cells, in combination with
cetuximab, induced apoptosis of TNBC cells while CD32A131R-CR
T cells, in combination with either cetuximab or panitumumab,
clearly induced MDA-MB-468 apoptosis. Interestingly,
CD32A131R-CR, in combination with 376.96 mAb triggered
detectable levels of MDA-MB-468 apoptosis (Fig. 4b). These data
show that the engineered T cells exert cytotoxic activity on MDA-
MB-468.
Crosslinking of CD16158F-CR on engineered T lympho-
cytes cultured with MDA-MB-468 BC cells promoted the
release of IFNγ (Fig. 5a) and TNFα (Fig. 5b) in the presence
of cetuximab but not panitumumab. In contrast, both anti-
EGFR mAbs and 376.96 mAbs triggered the release of both
cytokines by the CD32A131R-CR engineered T cells. Further-
more, although panitumumab and 376.96 mAb failed to medi-
ate cell-dependent cytotoxicity against the A549 and HCT116
cell lines, they induced a significant release of IFNγ by the
CD32A131R-CR T cells (Fig. 5a) incubated with the two cell
lines.
Correlation of EGFR expression level on targeted cancer
cell lines with the cetuximab-dependent Fcγ-CR T-cell
cytotoxicity
Our results indicate that, among the evaluated EGFR+ ECC
lines, only the MDA-MB-468 cells were efficiently killed by
the CD16158F-CR T cells in combination with cetuximab and
by the CD32A131R-CR T cells in combination with cetuximab
or panitumumab (Fig. 4). Because MDA-MB-468 cells express
high levels of EGFR,15 we hypothesized that the ability of
cetuximab to mediate the ADCC activity of Fcγ-CR T cells
against ECCs is associated with the EGFR expression level on
the target cells. To test this hypothesis, we measured the
EGFR expression level on the surface of the HCT116, A549,
MDA-MB-231 and MDA-MB-468 cells, and we correlated it
with the ability of cetuximab to mediate Fcγ-CR T-cell cyto-
toxicity with the target cells (Fig. 6). As expected, the MDA-
MB-468 cells displayed the highest MFI upon indirect staining
Figure 3. CD32A131R-chimeric receptor (CR) and CD16158F-CR engineered T cells are cytotoxic and produce equivalent amounts of interferon
gamma (IFNγ) and tumor necrosis factor alpha (TNFα). (a) Redirected antibody-dependent-cellular-cytotoxicity (ADCC) against HCT116FcγR+
cells. The CD32A131R-CR T cells or CD16158F-CR T cells were incubated with HCT116FcγR+ for 48 hr, at 37C, at an E:T ratio of 5:1, with or
without 8.26 (anti-CD32) or 3g8 (anti-CD16) mAbs. The viability of the HCT116FcγR+ cells was evaluated using the MTT assay. (b) Plastic bound
8.26 mAb or 3g8 mAb induces IFNγ and TNFα release in culture supernatants of Fcγ-CR T cells. After crosslinking of CD32A131R-CR or
CD16158F-CR by plastic coated 8.26 or 3g8, as described in the “Methods” section, the Fcγ-CR T-cell supernatants were collected and the IFNγ
and TNFα contents were measured by ELISA.
Figure 4. CD32A131R-chimeric receptor (CR) T cells eliminate MDA-MB-468 cells more efficiently than CD16158F-CR T cells. The antitumor 
activity of the CD32A131R-CR T cells and CD16158F-CR T cells was tested in combination with the indicated mAbs against the EGFR+ and B7-H3+ 
cancer cells. Triple negative breast cancer cells, MDA-MB-468 and KRAS-mutated MDA-MB-231, nonsmall cell lung cancer cells A549 and CRC 
cells HCT116, were chosen as the target cells. (a) MTT assays of tumor cell viability were performed after 48 hr incubation, at 37C, with 
CD32A131R-CR or CD16158F-CR T cells, with or without mAbs. The figure shows the cumulative data, with mean  SD values, of tumor cell 
viability obtained from three different donors at an E:T ratio of 5:1. Asterisks indicate: * = p < 0.05 and *** = p < 0.001. (b) Flow cytometry 
based-cytotoxic assay. CD16158F-CR T cells and CD32A131R-CR T cells were incubated at 37C in  5% CO2, in the presence or absence of
cetuximab (3 μg/ml) and panitumumab (3 μg/ml), with or without MDA-MB-468 at an E:T ratio of 1:1. After a 4 hr incubation, the cell mix was 
harvested and stained with PE-antihuman-EGFR mAb, FITC-Annexin V and PI. MDA-MB-468 cells were identified by posting an electronic gate 
of EGFR+ cells. Numbers in the quadrants indicate percentages of cells after gating on MDA-MB-468 cells.
with an anti-EGFR mAb (Fig. 6a). Furthermore, we assessed
the ability of both CD16158F-CR and CD32A131R-CR to reduce
the viability of EGFR+ ECCs in combination with cetuximab.
The CD16158F-CR and to a lesser extent CD32131R-CR corre-
lated with the MFI of the target marker by the cancer cell lines
that were tested (Fig. 6b).
Discussion
Rituximab and trastuzumab have been used to redirect first and
second generation CD16158V-CR T cells against CD20+ and
HER2+ hematologic and solid malignancies, respectively.9,11,12
The results obtained in preclinical studies suggest that
CD16158V-CR T cells may act as universal CR-effector cells
capable of improving the therapeutic effectiveness of TA-
specific mAbs by an ADCC mechanism. The rationale underly-
ing the choice of the high-affinity extracellular CD16158V for
manufacturing Fc chimeras is that CD16 triggers ADCC in NK
cells.16 However, myeloid cells, such as monocyte/macrophages
and granulocytes, can also mediate effector functions, such as
proinflammatory cytokine production17,18 and cell-mediated
cytotoxicity,19 including ADCC.20,21 Although CD16 is the
major player in mediating ADCC, CD32A is also capable of
promoting ADCC by myeloid cells.20 Similarly to CD16,
CD32A is characterized by low (CD32A131R) and high affinity
(CD32A131H) polymorphisms.3
To date, there is scant information about the antitumor
activity of CD16158F-CR T cells, and the role of CD32A131R-
CR T cells is completely unknown. Increasingly, experimental
evidence suggests that CD16158F and CD32A131R polymor-
phisms show differential binding affinities for the mAb Fc
portions of IgG1 and IgG2. Taking advantage of the availabil-
ity of cetuximab (IgG1) and panitumumab (IgG2), we demon-
strate, for the first time, that both CD32A131R-CR T cells and
CD16158F-CR T cells trigger ADCC to the TNBC cells, MDA-
MB-468. In a side-by-side comparison, we show the superior-
ity of CD32A131R-CR over CD16158F-CR in redirecting
engineered T cells against the MDA-MB-468 cells through
anti-EGFR mAbs, at least in vitro.
The affinity of CD16158F-CR and CD32A131R-CR for IgG1
and IgG2 mAbs was significantly different. The CD32A131R-CR
bound Fc fragments of soluble IgG1 (anti-CD107A and
cetuximab), and, to a lesser extent IgG2 (panitumumab),
whereas CD16158F-CR T cells bound neither cetuximab nor
panitumumab. The differential binding ability of cetuximab
and panitumumab to CD32A131R-CR is not surprising, because
the CD32A131R polymorphisms bind IgG1 with a significantly
Figure 5. CD32A131R-chimeric receptor (CR) T cells secrete interferon gamma (IFNγ) and tumor necrosis factor alpha (TNFα) more efficiently
than CD16158F-CR T cells after their conjugation with MDA-MB-468 cells by anti-EGFR mAbs. Supernatants were harvested after a 48 hr
culture, at 37C, of EGFR+ and B7-H3+ tumor target cells with CD16158F-CR T cells or CD32A131R-CR T cells, in the presence or absence of the
indicated mAbs. The release of IFNγ (a) and TNFα (b) was measured in the culture supernatants by specific ELISA. The figure shows the
cumulative data, with mean  SD values, of three different experiments performed at a 5:1 E:T ratio. Asterisks indicate: * = p < 0.05,
** = p < 0.01, *** = p < 0.001 and **** = p < 0.0001.
the CD32A131R-CR T cells, in combination with cetuximab,
neither released IFNγ and TNFα nor eliminated the KRAS-
mutated ECCs, including the A549, HCT116 and MDA-MB-
231 cells,22,23 although they were fully activated by the EGFR
overexpressing MDA-MB-468 cells.
The differential antitumor activity of both the Fcγ-CR
T cells with wild-type and KRAS-mutated ECC cells should
be addressed. The inability of both Fcγ-CR T cells to eliminate
the KRAS-mutated ECC cells does not reflect a mechanism of
resistance of these target cells to the lytic activity of the two
effector cells that were tested, because both of them can elimi-
nate KRAS-mutated HCT116FcγR+ cancer cells in a redirect
ADCC assay. However, the higher sensitivity of the wild-type
MDA-MB-468 in comparison to the tested KRAS-mutated
ECCs is likely to reflect the differential levels of surface EGFR
expression. Our data are also supported by Correale et al.,
who showed that drug-mediated upregulation of EGFR
enhanced the susceptibility of EGFR+ colorectal carcinoma
(CRC) cells to cetuximab-based ADCC of LAK cells.24 Indeed,
the KRAS wild-type, MDA-MB-468 cells overexpress EGFR25
at a level higher than the KRAS-mutated ECCs used in the
Figure 6. In vitro elimination of EGFR+ epithelial cancer cells (ECCs) by CD32A131R-chimeric receptor (CR) and CD16158F-CR T cells is
associated with EGFR overexpression. (a) EGFR expression levels in the tumor cell lines as assessed by flow cytometry. The cells were
incubated with 3 μg/ml of purified anti-EGFR antibody, washed and then stained with a phycoerythrin (PE)-conjugated antimouse IgG
(gray filled histograms). The cells incubated with PE-conjugated antimouse IgG were used as a negative control (light gray filled histograms).
Mean fluorescence intensity (MFI) is indicated for each cell line. (b) Spearman’s correlation between EGFR expression levels (MFI) in the
HCT116, A549, MDA-MB-231 and MDA-MB-468 cell lines and the ECC elimination by CD16158F-CR T cells (left panel) and CD32A131R-CR T cells
(right panel) in combination with cetuximab. A regression line is shown in black. Spearman’s rank correlation coefficient (r) was 0.6316 for
CD16158F-CR and 0.533 for CD32A131R-CR. This is a cumulative analysis of five experiments separately performed: 116 = HCT116, 231 = MDA-
MB-231, 468 = MDA-MB-468 and 549 = A549 cells.
higher affinity than IgG2. However, the failure of CD16158F-CR 
to bind soluble cetuximab (IgG1) is surprising, because 
CD16158F polymorphism has a slightly lower ability to bind 
IgG1 than CD32A131R.3 Our results are a bit different from 
those reported by Kudo et al.,9 who showed weak, but detect-
able, binding of soluble IgG1 mAbs, such as rituximab and 
trastuzumab, to CD16158F-CR. The differences in our results 
and the results reported by Kudo et al.9 may reflect structural 
differences between the CD16158F-CR endodomain.
The induction of an effective ADCC of tumor cells by 
FcγR+ cytotoxic T cells needs to meet at least three distinct 
criteria: (i) the presence of FcγR+ cytotoxic T cells with a 
functional lytic machinery; (ii) FcγR binding affinity for the 
tested mAb Fc fragment, sufficient to activate T cells; and (iii) 
surface expression level of the antigen targeted by the tested 
mAb, sufficient to activate the effector mechanisms in T cells. 
Indeed, both the CD16158F-CR- and CD32A131R-CR-
engineered T cells fully satisfy the first condition, because 
anti-CD16 mAb and anti-CD32 mAb triggered a similar level
of reverse ADCC when tested with KRAS-mutated, FcγR posi-
tive, HCT116 cells. However, the CD16158F-CR T cells and
present study. Our hypothesis is supported by Derer et al.’s
finding that a KRAS mutation impairs the sensitivity of CRC
cells to anti-EGFR mAbs due to C/EBPβ-dependent down-
regulation of EGFR expression.26
The restoration of the sensitivity of the KRAS-mutated
ECCs to Fcγ-CR T-cell lytic activity may require the genera-
tion of CD32A-CR and CD16-CR with high affinity for the
used mAb Fc fragments, such as CD32A131H-CR and
CD16158V-CR. This strategy is supported by the ability of
ECCs opsonized with anti-EGFR mAbs to induce a level of
FcγR crosslinking insufficient to fully mediate ADCC, but suf-
ficient to stimulate other Fcγ-CR T-cell functions, such as
cytokine production. In support of this, we show that
HCT116 and A549 cells, opsonized with panitumumab or
376.96 mAb, promote IFNγ release from CD32A131R-CR
T cells. In this context, we were surprised to see that
CD32A131R-CR T cells combined with the IgG2, 376.96 mAb
(anti-B7-H3) induced MDA-MB-468 apoptosis and cytokine
release while no antitumor effects were detected by the MTT
assay. These results may be explained by the possibility that
the sensitivity of the two assays differ.
The failure to generate an effective ADCC could be related
to inadequate expression of EGFR on the surface of ECCs. In
support of this hypothesis, CD16158F-CR T and CD32A131R-
CR T cells, in combination with cetuximab, damaged the
wild-type MDA-MB-468 cells overexpressing EGFR. Indeed,
the results shown in Fig. 6 indicate that the extent of ECC
reduced viability induced by the combination of either the
CD16158F-CR T cells or CD32A131R-CR T cells with
cetuximab directly correlated with the EGFR expression levels
on the targeted ECCs. EGFR crosslinking on MDA-MB-468
cells, with Fcγ-CR T cells and cetuximab, led to ADCC activa-
tion. The ability of the CD16158F-CR T cells to mediate ADCC
in the presence of cetuximab was somewhat unexpected
because no binding of soluble cetuximab to these cells could
be detected. This finding may reflect the ability of CD16158F-
CR T cells to bind cetuximab only after EGFR cancer cell
opsonization, which stabilizes the ligand-receptor interactions.
Unlike cetuximab (IgG1), panitumumab (IgG2) did not
induce significant ADCC by NK cells, thereby limiting its
applications in cell-based cancer immunotherapy.27 However,
panitumumab is still able to trigger ADCC by macrophages,
which, with the exception of a small subset of cells,28 do not
express CD16, but do express CD32 and CD64.29 As a logical
consequence, engineering cytotoxic T cells with a CD32A131R-CR
has allowed us to demonstrate that panitumumab can stimulate
strong ADCC by CD32A131R-CR T cells against MDA-MB-468
cells overexpressing EGFR. These results provide new perspectives
for the use of panitumumab in cell-based targeted immunother-
apy of solid tumors.
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